These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 17213251

  • 1. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
    Heiberg MS, Kaufmann C, Rødevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, Kvien TK.
    Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251
    [Abstract] [Full Text] [Related]

  • 2. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2008 Feb 15; 59(2):234-40. PubMed ID: 18240258
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rødevand E, Kaufmann C, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2010 Apr 15; 69(4):671-6. PubMed ID: 19740904
    [Abstract] [Full Text] [Related]

  • 4. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, Kalstad S, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2014 Jan 15; 73(1):132-7. PubMed ID: 23291385
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
    Kristensen LE, Gülfe A, Saxne T, Geborek P.
    Ann Rheum Dis; 2008 Mar 15; 67(3):364-9. PubMed ID: 17644547
    [Abstract] [Full Text] [Related]

  • 6. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug 15; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 7. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul 15; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 8. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
    Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A.
    Ann Rheum Dis; 2009 Dec 15; 68(12):1856-62. PubMed ID: 19126559
    [Abstract] [Full Text] [Related]

  • 9. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P.
    Rheumatology (Oxford); 2006 Aug 15; 45(8):1029-38. PubMed ID: 16782734
    [Abstract] [Full Text] [Related]

  • 10. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
    van Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A, ADORE Study Investigators.
    Ann Rheum Dis; 2008 Aug 15; 67(8):1104-10. PubMed ID: 17666447
    [Abstract] [Full Text] [Related]

  • 11. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P.
    Rheumatology (Oxford); 2008 Apr 15; 47(4):495-9. PubMed ID: 18316338
    [Abstract] [Full Text] [Related]

  • 12. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
    Eder L, Thavaneswaran A, Chandran V, Gladman DD.
    Ann Rheum Dis; 2014 Jun 15; 73(6):1007-11. PubMed ID: 23619157
    [Abstract] [Full Text] [Related]

  • 13. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec 15; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 14. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF, GISEA group.
    J Rheumatol; 2007 Aug 15; 34(8):1670-3. PubMed ID: 17611987
    [Abstract] [Full Text] [Related]

  • 15. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
    Chen JS, Makovey J, Lassere M, Buchbinder R, March LM.
    Arthritis Care Res (Hoboken); 2014 Mar 15; 66(3):464-72. PubMed ID: 24022870
    [Abstract] [Full Text] [Related]

  • 16. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
    Finzel S, Kraus S, Schmidt S, Hueber A, Rech J, Engelke K, Englbrecht M, Schett G.
    Ann Rheum Dis; 2013 Jul 15; 72(7):1176-81. PubMed ID: 22915620
    [Abstract] [Full Text] [Related]

  • 17. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P.
    Arthritis Rheum; 2011 Dec 15; 63(12):3723-32. PubMed ID: 21834061
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
    Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, Bensen W, Syrotuik J, Poulin-Costello M.
    J Rheumatol; 2011 Jul 15; 38(7):1355-62. PubMed ID: 21572156
    [Abstract] [Full Text] [Related]

  • 19. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
    Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, Landewé R, Steinfeld SD, Emery P, Dijkmans BA, Veale DJ.
    Ann Rheum Dis; 2005 Jun 15; 64(6):859-64. PubMed ID: 15528283
    [Abstract] [Full Text] [Related]

  • 20. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.
    Iannone F, Fanizzi R, Scioscia C, Anelli MG, Lapadula G.
    Scand J Rheumatol; 2013 Jun 15; 42(1):41-4. PubMed ID: 22991950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.